3 research outputs found
Lymphatic filariasis in Fiji: progress towards elimination, 1997–2007
Background: Lymphatic filariasis (LF) is a major public health problem in the Pacific Region, including in Fiji.
Through transmission by the mosquito vector Aedes, Fiji has suffered the burden of remaining endemic with LF
despite efforts at elimination prior to 1999. In the year 1999, Fiji agreed to take part in the Pacific Programme for Elimination of LF (PacELF) and the Global Programme to Eliminate LF.
Methods: This study reviewed and collated past data on LF in Fiji between 1997 and 2007. Sources included
published papers as well as unpublished PacELF and WHO program meeting and survey reports. Records were held
at Fiji’s Department of Health and Medical Services, James Cook University and the WHO office in Suva, Fiji.
Results: Baseline surveys between 1997 and 2002 showed that Fiji was highly endemic for LF with an estimated
16.6% of the population antigen positive and 6.3% microfilaria positive at that time. Five rounds of annual mass drug administration (MDA) using albendazole and diethylcarbamazine commenced in 2002. Programmatic
coverage reported was 58–70% per year, but an independent coverage survey in 2006 in Northern Division after
the fifth MDA suggested that actual coverage may have been higher. Monitoring of the program consisted of
antigen prevalence surveys in all ages with sentinel and spot check surveys carried out in 2002 (pre MDA), 2004,
and 2005, together with knowledge, attitude, and practice surveys. The stop-MDA survey (C survey) in 2007 was a
nationwide stratified cluster survey of all ages according to PacELF guidelines, designed to sample by administrative
division to identify areas still needing MDA. The national antigen prevalence in 2007 was reduced by more than a
third to 9.5%, ranging from 0.9% in Western Division to 15.4% in Eastern Division, while microfilaria prevalence was reduced by almost four-fifths to 1.4%. Having not reached the target threshold of 1% prevalence in all ages, Fiji wisely decided to continue MDA after 2007 but to move from nationwide implementation to four (later five) separate evaluation units with independent timelines using global guidelines, building on program experience to put more emphasis on increasing coverage through prioritized communication strategies, community participation, and morbidity alleviation.
Conclusion: Fiji conducted nationwide MDA for LF annually between 2002 and 2006, monitored by extensive
surveys of prevalence, knowledge, and coverage. From a high baseline prevalence in all divisions, large reductions in overall and age-specific prevalence were achieved, especially in the prevalence of microfilariae, but the threshold for stopping MDA was not reached. Fiji has a large rural and geographically widespread population, program management was not consistent over this period, and coverage achieved was likely not optimal in all areas. After learning from these many challenges and activities, Fiji was able to build on the progress achieved and the heterogeneity observed in prevalence to realign towards a more stratified and improved program after 2007. The information presented here will assist the country to progress towards validating elimination in subsequent years
The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific
We discuss the experience of some Pacific island countries in introducing the new WHO-recommended treatment protocol for lymphatic filariasis—a triple-drug therapy composed of ivermectin, diethylcarbamazine, and albendazole. The successful rollout of the new treatment protocol was dependent on strong partnerships among these countries’ ministries of health, WHO, and other stakeholders. Effective communication among these partners allowed for lessons learned to cross borders and have a positive impact on the experiences of other countries. We also describe various challenges confronted during this process and the ways these countries overcame them
Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji.
Zika virus (ZIKV) has caused large, brief outbreaks in isolated populations, however ZIKV can also persist at low levels over multiple years. The reasons for these diverse transmission dynamics remain poorly understood. In Fiji, which has experienced multiple large single-season dengue epidemics, there was evidence of multi-year transmission of ZIKV between 2013 and 2017. To identify factors that could explain these differences in dynamics between closely related mosquito-borne flaviviruses, we jointly fit a transmission dynamic model to surveillance, serological and molecular data. We estimate that the observed dynamics of ZIKV were the result of two key factors: strong seasonal effects, which created an ecologically optimal time of year for outbreaks; and introduction of ZIKV after this optimal time, which allowed ZIKV transmission to persist over multiple seasons. The ability to jointly fit to multiple data sources could help identify a similar range of possible outbreak dynamics in other settings